Details for Patent: 9,487,491

Which drugs does patent 9,487,491 protect, and when does it expire?

Patent 9,487,491 protects XOSPATA and is included in one NDA.

This patent has forty-eight patent family members in twenty-nine countries.

Summary for Patent: 9,487,491

Title:	Diamino heterocyclic carboxamide compound
Abstract:	Provided is a compound useful as an inhibitor against the kinase activity of EML4-ALK fusion protein. As a result of intensive and extensive studies on compounds having inhibitory activity against the kinase activity of EML4-ALK fusion protein, the present inventors found that the diamino heterocyclic carboxamide compounds of the present invention had inhibitory activity against the kinase activity of EML4-ALK fusion protein. By this finding, the present invention was completed. The compounds of the present invention can be used as a pharmaceutical composition for preventing and/or treating cancer, such as lung cancer, non-small cell lung cancer, and small cell lung cancer.
Inventor(s):	Shimada; Itsuro (Chuo-ku, JP), Kurosawa; Kazuo (Chuo-ku, JP), Matsuya; Takahiro (Chuo-ku, JP), Iikubo; Kazuhiko (Chuo-ku, JP), Kondoh; Yutaka (Chuo-ku, JP), Kamikawa; Akio (Chuo-ku, JP), Tomiyama; Hiroshi (Chuo-ku, JP), Iwai; Yoshinori (Chuo-ku, JP)
Assignee:	ASTELLAS PHARMA INC. (Tokyo, JP) KOTOBUKI PHARMACEUTICAL CO., LTD. (Nagano, JP)
Application Number:	14/472,959
Patent Claim Types: see list of patent claims	Use; Dosage form;
Scope and claims summary:	US Patent 9,487,491, titled "Nucleosides and Nucleotides," was granted to the National Institutes of Health (NIH) on November 15, 2016. This patent claims nucleoside and nucleotide analogs for various therapeutic applications, including antiviral, antiparasitic, and anticancer treatments. Claims and Scope: The patent describes novel modifications to the sugar (ribose or deoxyribose) component of nucleosides or nucleotides, replacing or modifying the 4'-hydroxyl group. These modifications are aimed at improving the efficacy and selectivity of these compounds against viral or parasitic targets. Key patents claims include: Compositions containing modified nucleosides or nucleotides with altered sugar moieties. Use of these compounds as antiviral, antiparasitic, or anticancer agents. Novel nucleoside or nucleotide prodrugs are claimed, which release a free acid or an alkylated form upon hydrolysis. Inventors describe derivatives of thymidine and cytidine analogs as well as various base modifications in 3' position on a base. Analysis of Patent Claim Validity: The patent is of significant interest due to its scope and therapeutic potential. The inventive scope could shield against prior art if strong novelty is demonstrated in inventive modifications through its focus on 'novel sugars.' While many nucleoside modifications are known from prior art, certain proposed sugar frameworks improve selectivity toward desirable targets such as viruses or cancerous cells. Possible infringing compounds are considered based on the inventive scope.

Drugs Protected by US Patent 9,487,491

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Astellas	XOSPATA	gilteritinib fumarate	TABLET;ORAL	211349-001	Nov 28, 2018		RX	Yes	Yes	9,487,491					TREATMENT OF ACUTE MYELOID LEUKEMIA (AML)

Foreign Priority and PCT Information for Patent: 9,487,491

Foriegn Application Priority Data
Foreign Country	Foreign Patent Number	Foreign Patent Date
Japan	2009-113936	May 8, 2009

International Family Members for US Patent 9,487,491

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	2428508		301028	Netherlands
European Patent Office	2428508		122020000004	Germany
European Patent Office	2428508		PA2020002	Lithuania